Novartis secures approval for AMD drug in Australia Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country.Read More Myles HumeJanuary 29, 2020, 8:38 amJanuary 29, 2020